11 Insulin-Dependent Diabetes Mellitus

Also Known As:

Diabetes Mellitus, Insulin-Dependent, 11; IDDM11; Insulin-Dependent Diabetes Mellitus 11

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Disease Context: Research Results

Nutritional and Metabolic Diseases: 15
- Metabolic Diseases: 10142
  - Glucose Metabolism Disorders: 375
    - Diabetes Mellitus: 56563
      - Type 1 Diabetes Mellitus: 36799
        11 Insulin-Dependent Diabetes Mellitus: 4
Endocrine System Diseases: 968
- Diabetes Mellitus: 56563
  - Type 1 Diabetes Mellitus: 36799
    - 11 Insulin-Dependent Diabetes Mellitus: 4
Immune System Diseases: 4321
- Autoimmune Diseases: 34618
  - Type 1 Diabetes Mellitus: 36799
    - 11 Insulin-Dependent Diabetes Mellitus: 4

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to 11 Insulin-Dependent Diabetes Mellitus:

1.	Captopril (Capoten)FDA LinkGeneric 07/01/1990 - "We therefore conducted a double-blind, placebo-controlled, crossover trial to compare 3 months of treatment with the angiotensin converting enzyme inhibitor captopril (0.9 mg/kg/day), and 3 months of placebo administration to 12 normotensive adolescents with insulin-dependent diabetes mellitus, 11 with microalbuminuria (albumin excretion rate of 15 to 200 micrograms/min) and one with early overt nephropathy. "
2.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 07/01/1990 - "We therefore conducted a double-blind, placebo-controlled, crossover trial to compare 3 months of treatment with the angiotensin converting enzyme inhibitor captopril (0.9 mg/kg/day), and 3 months of placebo administration to 12 normotensive adolescents with insulin-dependent diabetes mellitus, 11 with microalbuminuria (albumin excretion rate of 15 to 200 micrograms/min) and one with early overt nephropathy. "
3.	AlbuminsIBA 07/01/1990 - "We therefore conducted a double-blind, placebo-controlled, crossover trial to compare 3 months of treatment with the angiotensin converting enzyme inhibitor captopril (0.9 mg/kg/day), and 3 months of placebo administration to 12 normotensive adolescents with insulin-dependent diabetes mellitus, 11 with microalbuminuria (albumin excretion rate of 15 to 200 micrograms/min) and one with early overt nephropathy. "
4.	Norepinephrine (Noradrenaline)FDA LinkGeneric 11/01/1990 - "The influence of metabolic control (HbA1c), noradrenaline (NA) and insulin-like growth factors (IGF-I and IGF-II) on renal function and size was investigated in 11 insulin-dependent diabetes mellitus patients aged 11-17 years. "
5.	Isophane Insulin (NPH Insulin)FDA Link 01/01/1990 - "To evaluate the importance of accidental intramuscular injection of NPH insulin, we measured disappearance rates of 125I-labeled NPH insulin (Protaphane) from subcutaneous and intramuscular injection sites in the thighs of 11 insulin-dependent diabetes mellitus patients. "
6.	Insulin-Like Growth Factor II (Somatomedin A)IBA 11/01/1990 - "The influence of metabolic control (HbA1c), noradrenaline (NA) and insulin-like growth factors (IGF-I and IGF-II) on renal function and size was investigated in 11 insulin-dependent diabetes mellitus patients aged 11-17 years. "
7.	Insulin-Like Growth Factor I (IGF-1)IBA 11/01/1990 - "The influence of metabolic control (HbA1c), noradrenaline (NA) and insulin-like growth factors (IGF-I and IGF-II) on renal function and size was investigated in 11 insulin-dependent diabetes mellitus patients aged 11-17 years. "
8.	Insulin (Novolin)FDA Link 01/01/1999 - "The IDDM11 locus has been mapped in this region, and TSA305 may represent a candidate gene for predisposition in some families whose insulin-dependent diabetes is not linked to the HLA locus."
9.	Insulin-Like PeptidesIBA 11/01/1990 - "The influence of metabolic control (HbA1c), noradrenaline (NA) and insulin-like growth factors (IGF-I and IGF-II) on renal function and size was investigated in 11 insulin-dependent diabetes mellitus patients aged 11-17 years. "

Therapies and Procedures

1.	Intramuscular Injections 01/01/1990 - "To evaluate the importance of accidental intramuscular injection of NPH insulin, we measured disappearance rates of 125I-labeled NPH insulin (Protaphane) from subcutaneous and intramuscular injection sites in the thighs of 11 insulin-dependent diabetes mellitus patients. "